Everus Board Authorizes New $100 Million Share Repurchase Program Through 2029
ECG sits 25% above its 52-week low of $70.44.
Summary
Everus authorized a new $100 million share repurchase program, effective immediately and running through December 15, 2029. No shares have been bought yet — the board retains full discretion to size, time, or cancel repurchases.
Key Events · Financing and Capital Events · ECG
-
New $100M Buyback Authorized
The board approved a share repurchase program for up to an aggregate of $100.0 million of outstanding common stock, effective immediately.
-
No Repurchases Executed Yet
The authorization is discretionary; the number, price, structure and timing of any repurchases are at the company's sole discretion, and no shares have been bought under the program.
-
Program Runs to December 2029
The program expires December 15, 2029, and may be suspended, modified or terminated at any time without prior notice.
-
Debt Covenants Constrain Repurchases
Future repurchases will be evaluated against market conditions, liquidity needs and restrictions under the company's debt arrangements.
Analysis · ECG · Real Estate & Construction
For a company this size, a $100 million buyback authorization is meaningful: it gives management real capacity to retire stock and signals the board views the shares as a good use of cash. The move follows a strong Q3 (40% revenue growth to $1.38 billion, $1.79 diluted EPS) and the completed $295 million Epsilon Industries acquisition, so the message is that Everus can fund both acquisitions and buybacks. The catch is that this is permission, not action. No shares have been repurchased, the program runs to December 15, 2029, and it can be suspended or terminated at any time, so actual repurchases will depend on cash needs and debt covenants.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ECG was trading at $88.20 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $70.44 to $171.58. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.